Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01458964 · ClinicalTrials.gov registry record · Phase 4

Quetiapine Compared With Placebo in the Management of Fibromyalgia

A Phase 4 study of Fibromyalgia, sponsored by East Tennessee State University.

Completed
Registry status
Phase 4
Development phase
42
Enrollment target
1
Study location

NCT01458964: Completed Phase 4 study of Fibromyalgia, sponsored by East Tennessee State University.

NCT01458964 is a Phase 4 study of Fibromyalgia that has completed, run by East Tennessee State University. The registered enrollment target is 42 participants, below the 179-participant average among 76 other Fibromyalgia trials with a reported enrollment target (77% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01458964, a Phase 4 study of Fibromyalgia, has completed, sponsored by East Tennessee State University.

COMPLETED
Registry status
Phase 4
Development phase
42 participants
Enrollment target
1
Study location

Study Summary

Is quetiapine more effective than other medications in the treatment of fibromyalgia.

Conditions Studied

Interventions

  • DRUG Quetiapine

Study Locations (1)

Tennessee

  • East Tennessee State University - Johnson City

Trial Details

FieldValue
Enrollment Target 42 participants
Start Date 2008-01
Est. Completion 2013-12
Phase Phase 4
East Tennessee State University

16 total trials

What the finished NCT01458964 record still lists

NCT01458964 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 42 participants, a relatively small participant target, below the 179-participant average among 76 other Fibromyalgia trials with a reported enrollment target (77% lower).

The record links to 1 condition, with Fibromyalgia appearing as the primary indexed condition, and to 1 intervention - of which Quetiapine is the first listed.

NCT01458964 reports a single indexed study location in Tennessee.

Frequently Asked Questions

What is clinical trial NCT01458964 about?

NCT01458964 is a clinical study titled "Quetiapine Compared With Placebo in the Management of Fibromyalgia". Is quetiapine more effective than other medications in the treatment of fibromyalgia.

What is the current status of trial NCT01458964?

This trial is currently completed. It is a Phase 4 study. The enrollment target is 42 participants. The study started on 2008-01. Estimated completion is 2013-12.

What conditions does trial NCT01458964 study?

This clinical trial studies the following conditions: Fibromyalgia.

What interventions are being tested in trial NCT01458964?

The interventions under investigation include: Quetiapine (DRUG).

Who is sponsoring clinical trial NCT01458964?

This trial is sponsored by East Tennessee State University, which has 16 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01458964 being conducted?

This trial has 1 study location across Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Fibromyalgia

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT01458964's enrollment target sits among peer trials

42 53rd of 76 higher than 24 of 76 other Fibromyalgia trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Fibromyalgia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02852213 · 42 participants · Phase 1

    A Single-Stage, Adaptive, Open-label, Dose Escalation Safety and Efficacy Study of AADC Deficiency in Pediatric Patients

  • NCT03136146 · 42 participants · Phase 2

    Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma, Burkitt Lymphoma/Leukemia, or Double-Hit Lymphoma/Leukemia

  • NCT03178149 · 42 participants · Phase 1

    A Study of the Safety and Tolerability of ASP7317 in Senior Adults Who Are Losing Their Clear, Sharp Central Vision Due to Geographic Atrophy Secondary to Dry Age-related Macular Degeneration

  • NCT03663530 · 42 participants · NA

    Circadian Misalignment and Energy Balance

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT01458964, the US trial registry maintained by the National Library of Medicine. NCT01458964 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.